{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:39:44Z","timestamp":1791725984866,"version":"4.3.4"},"reference-count":30,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MedComm"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    This study evaluated the safety, tolerability, and pharmacokinetics of JBD0131, a novel nitroimidazooxazole antitubercular agent, in healthy adults. We previously reported JBD0131, a novel nitroimidazooxazole antitubercular agent, which overcomes drug resistance and bioavailability limitations of existing anti\u2010tuberculosis therapies. The clinical trial was structured into three parts: an initial single ascending dose (SAD) phase under fasting conditions, a food\u2010effect assessment, and a final multiple ascending dose (MAD) phase conducted after meals. \u00a0Among 95 enrolled participants, JBD0131 demonstrated favorable safety and tolerability across all regimens. No serious adverse events (AEs) or treatment discontinuations occurred. Treatment\u2010emergent AE incidence was comparable to placebo without dose\u2010dependent trends. Pharmacokinetic (PK) analysis showed that systemic exposure for JBD0131, measured by maximum plasma concentration (\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ) and area under the plasma concentration\u2013time curve (AUC), increased proportionally with the dose. The presence of food significantly enhanced the bioavailability and delayed the median time to reach peak concentration (\n                    <jats:italic>T<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ) by approximately 2 h. These findings collectively demonstrate that JBD0131 has an acceptable safety profile and predictable, linear pharmacokinetics in healthy adults. The observed food effect, which boosts systemic exposure, along with the drug's linear accumulation, supports the need for further investigation to define optimal treatment regimens for future clinical development.\n                  <\/jats:p>","DOI":"10.1002\/mco2.70510","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:09:27Z","timestamp":1764918567000},"source":"Crossref","is-referenced-by-count":2,"title":["Safety, Tolerability, and Pharmacokinetics of a Novel Nitroimidazooxazole Antitubercular Agent in Healthy Adults: A Phase I Trial"],"prefix":"10.1002","volume":"6","author":[{"given":"Jia","family":"Miao","sequence":"first","affiliation":[{"name":"GCP Center\/Institute of Drug Clinical Trials West China Hospital Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenling","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory of Aging Research and Cancer Drug Target National Clinical Research Center for Geriatrics State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huashan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Qin","sequence":"additional","affiliation":[{"name":"GCP Center\/Institute of Drug Clinical Trials West China Hospital Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantao","family":"Gao","sequence":"additional","affiliation":[{"name":"GCP Center\/Institute of Drug Clinical Trials West China Hospital Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Jiang","sequence":"additional","affiliation":[{"name":"Jumbo Drug Bank Co., Ltd  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine State Key Laboratory of Respiratory Health and Multimorbidity West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manni","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-6422","authenticated-orcid":false,"given":"Xiawei","family":"Wei","sequence":"additional","affiliation":[{"name":"Laboratory of Aging Research and Cancer Drug Target National Clinical Research Center for Geriatrics State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University  Chengdu China"},{"name":"Jumbo Drug Bank Co., Ltd  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"https:\/\/www.who.int\/teams\/global\u2010programme\u2010on\u2010tuberculosis\u2010and\u2010lung\u2010health\/tb\u2010reports\/global\u2010tuberculosis\u2010report\u20102024."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.10.023"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2020.04.010"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2020.126674"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneumo.2014.09.001"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100249"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00134-4"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30247-0"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.09.004"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.12.010"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1206056"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767140-00007"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.10.008"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz914"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.15190\/d.2019.15"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574891X12666170619101904"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30366-2"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058606"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.10.0616"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.06.055"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.25122"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01159-w"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00180-19"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-00997-0"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01196-20"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01133-2"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00907-19"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.04.003"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01283"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093248"}],"container-title":["MedComm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mco2.70510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mco2.70510","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mco2.70510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T06:37:17Z","timestamp":1783838237000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mco2.70510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/mco2.70510"],"URL":"https:\/\/doi.org\/10.1002\/mco2.70510","archive":["Portico"],"relation":{},"ISSN":["2688-2663","2688-2663"],"issn-type":[{"value":"2688-2663","type":"print"},{"value":"2688-2663","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"e70510"}}